Oncternal Therapeutics Stock

Oncternal Therapeutics ROCE 2024

Oncternal Therapeutics ROCE

-1.39

Ticker

ONCT

ISIN

US68236P1075

WKN

A2PL3P

In 2024, Oncternal Therapeutics's return on capital employed (ROCE) was -1.39, a 88.29% increase from the -0.74 ROCE in the previous year.

Oncternal Therapeutics Aktienanalyse

What does Oncternal Therapeutics do?

Oncternal Therapeutics Inc is an American biotechnology company specializing in the development of cancer drugs. The company was founded in 2013 and is headquartered in San Diego, California. Oncternal Therapeutics' business model is based on identifying promising cancer drugs and advancing them through the approval process of regulatory authorities. The company utilizes both public and private funds to finance its research projects. As part of this, Oncternal Therapeutics participates in clinical trials and actively collaborates with experts in the clinical field. Over the years, the company has established several divisions to make its work more effective and efficient. One of these divisions focuses on developing molecules that activate the body's immune system against cancer cells. A prime example of this is the drug Cirmtuzumab. This antibody blocks signals that promote the growth of cancer cells while simultaneously activating the immune system to target tumor cells. Cirmtuzumab has shown positive results in the treatment of chronic lymphocytic leukemia, a form of blood cancer. Another division of Oncternal Therapeutics focuses on developing drugs that target cancer stem cells. These cells are responsible for the growth and spread of cancer cells in the body. Medications like the ROR1-targeting CAR-T preparation directly target these types of cancer cells and are intended to make cancer drugs more effective and targeted. Oncternal Therapeutics stands out from other cancer researchers in its ability to treat multiple myelomas, a cancer of the bone marrow cells, more effectively. The company has developed specific drugs that can influence the expression of specific genes in myeloma cells, thereby halting tumor growth. Key myeloma products from Oncternal Therapeutics include the TK216 and OT-82 preparations. In summary, Oncternal Therapeutics Inc is an innovative biotechnology company specializing in the development of cancer drugs. The company has a wide range of divisions, from developing drugs that activate the immune system against cancer cells to targeting cancer stem cells. The company's products show promising results in the treatment of various types of cancer and have the potential to bring about positive change for thousands of cancer patients worldwide. Oncternal Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Oncternal Therapeutics's Return on Capital Employed (ROCE)

Oncternal Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Oncternal Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Oncternal Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Oncternal Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Oncternal Therapeutics stock

What is the ROCE (Return on Capital Employed) of Oncternal Therapeutics this year?

The ROCE of Oncternal Therapeutics is -1.39 undefined this year.

How has the ROCE (Return on Capital Employed) of Oncternal Therapeutics developed compared to the previous year?

The ROCE of Oncternal Therapeutics has increased by 88.29% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Oncternal Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Oncternal Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Oncternal Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Oncternal Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Oncternal Therapeutics impact the company?

An increase in the ROCE of Oncternal Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Oncternal Therapeutics affect the company?

A decrease in ROCE of Oncternal Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Oncternal Therapeutics?

Some factors that can affect Oncternal Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Oncternal Therapeutics so important for investors?

The ROCE of Oncternal Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Oncternal Therapeutics take to improve the ROCE?

To improve the ROCE, Oncternal Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Oncternal Therapeutics pay?

Over the past 12 months, Oncternal Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncternal Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Oncternal Therapeutics?

The current dividend yield of Oncternal Therapeutics is .

When does Oncternal Therapeutics pay dividends?

Oncternal Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncternal Therapeutics?

Oncternal Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Oncternal Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncternal Therapeutics located?

Oncternal Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncternal Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncternal Therapeutics from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Oncternal Therapeutics pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Oncternal Therapeutics in the year 2023?

In the year 2023, Oncternal Therapeutics distributed 0 USD as dividends.

In which currency does Oncternal Therapeutics pay out the dividend?

The dividends of Oncternal Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncternal Therapeutics

Our stock analysis for Oncternal Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncternal Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.